Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

France’s Novacap To Acquire Uetikon

by Rick Mullin
May 18, 2015 | A version of this story appeared in Volume 93, Issue 20

[+]Enlarge
Credit: Uetikon
Uetikon added this 250-L reactor (portion shown) to its kilo lab last year.
Uetikon added this 250-L reactor to its kilolab last year.
Credit: Uetikon
Uetikon added this 250-L reactor (portion shown) to its kilo lab last year.

Novacap, a French specialty and pharmaceutical chemicals company, will acquire CU Chemie Uetikon, which provides custom synthesis of drug intermediates and active pharmaceutical ingredients from a plant in Lahr, Germany. The company, with 135 employees, had sales of $45 million last year. “The acquisition of Uetikon fits perfectly into our strategy to reinforce our position in pharmaceuticals and health markets,” says Novacap CEO Pierre Luzeau. Novacap was formed in 2003 through the acquisition of a Rhodia business.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.